Literature DB >> 7470733

Absence of changes in drug disposition and catecholamine sensitivity in the hyperthyroid dog.

T Ishizaki, K Tawara.   

Abstract

1 In order to study the relative contribution of hepatic drug metabolizing enzymes and hepatic blood flow to the clearance of drugs in the hyperthyroid state, the disposition kinetics of two model compounds (antipyrine and propranolol) were examined in thyroid-fed dogs as compared to euthyroid and phenobarbitone-pretreated animals. 2 In hyperthyroid dogs, the possibility of catecholamine hypersensitivity was evaluated by assessing the chronotropic response to isoprenaline and by constructing a drug concentration-effect (beta-blockade) relationship. 3 The plasma propranolol half-life (0.97 +/- 0.12 h) of the hyperthyroid animals did not differ significantly from either the euthyroid group or the phenobarbitone-pretreated group. This was observed with no significant change in the apparent volume of distribution among the three experimental groups. 4 Phenobarbitone pretreatment accelerated significantly the elimination of antipyrine (half-life, 1.09 +/- 0.15 h, P less than 0.01) as compared to the euthyroid (2.84 +/- 0.35 h) and the hyperthyroid groups (2.58 +/- 0.13 h), respectively, without any changes in the apparent volume of distribution in any group. 5 Neither the chronotropic responses to exogenously administered catecholamine, nor the antagonist concentration-effect relationships support the concept that the hyperthyroid state potentiates sensitivity of the receptor-effect system of the heart. 6 The data obtained from the present study fit best with the view that thyroid hormone excess alters neither the disposition of the model compounds used nor the catecholamine-sensitivity examined.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7470733      PMCID: PMC2044420          DOI: 10.1111/j.1476-5381.1980.tb10919.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  42 in total

1.  Studies of the effect of thyroid dysfunction on the elimination of beta-adrenoreceptor blocking drugs.

Authors:  J M Bell; C J Russell; J K Nelson; J G Kelly; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1977-02       Impact factor: 4.335

2.  Variable plasma propranolol levels in thyrotoxicosis.

Authors:  S Rubenfeld; V E Silverman; K M Welch; L E Mallette; P O Kohler
Journal:  N Engl J Med       Date:  1979-02-15       Impact factor: 91.245

3.  Effects of beta-adrenergic receptor blockade in normal subjects before, during, and after triiodothyronine-induced hypermetabolism.

Authors:  W R Wilson; E O Theilen; J H Hege; M R Valenca
Journal:  J Clin Invest       Date:  1966-07       Impact factor: 14.808

4.  Serum dopamine-beta-hydroxylase activity in thyroid disorders.

Authors:  Y Nishizawa; N Hamada; S Fujii; H Morii; K Okuda
Journal:  J Clin Endocrinol Metab       Date:  1974-09       Impact factor: 5.958

5.  Plasma propranolol levels in adults with observations in four children.

Authors:  D G Shand; E M Nuckolls; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

6.  Inhibition of the carotid sinus reflex by the chronic administration of propranolol.

Authors:  D Dunlop; R G Shanks
Journal:  Br J Pharmacol       Date:  1969-05       Impact factor: 8.739

7.  The effects of injected norepinephrine and sympathetic nerve stimulation in hypothyroid and hyperthyroid dogs.

Authors:  H S Margolius; T E Gaffney
Journal:  J Pharmacol Exp Ther       Date:  1965-09       Impact factor: 4.030

8.  Altered plasma half-lives of antipyrine, propylthiouracil, and methimazole in thyroid dysfunction.

Authors:  E S Vesell; J R Shapiro; T Passananti; H Jorgensen; C A Shively
Journal:  Clin Pharmacol Ther       Date:  1975-01       Impact factor: 6.875

Review 9.  Drug metabolism in thyroid disease.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

10.  Impairment of antipyrine clearance in humans by propranolol.

Authors:  D J Greenblatt; K Franke; D H Huffman
Journal:  Circulation       Date:  1978-06       Impact factor: 29.690

View more
  1 in total

1.  Pharmacokinetics and pharmacodynamics of propranolol stereoisomers in hyperthyroid patients.

Authors:  K Tawara; K Kawashima; H Ishikawa; K Yamamoto; K Saito; A Ebihara; S Yoshida
Journal:  Eur J Clin Pharmacol       Date:  1981-02       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.